Natasha K Martin1, Peter Vickerman, Gregory J Dore, Matthew Hickman. 1. aDivision of Global Public Health, University of California San Diego, San Diego, California, USA bSchool of Social and Community Medicine, University of Bristol, Bristol, UK cKirby Institute, UNSW Australia, Sydney, New South Wales, Australia.
Abstract
PURPOSE OF REVIEW: The burden of hepatitis C virus (HCV) is high among people who inject drugs (PWID) and prisoners, and increasing among HIV-infected MSM, who are key populations for HCV transmission in high-income countries and may also play a role in many in low- and middle-income countries. There is an increasing interest in the use of HCV antiviral treatment for prevention in these populations. RECENT FINDINGS: Numerous theoretical modelling studies have explored the potential impact of HCV treatment for prevention among PWID in a range of global settings, generally finding that modest and achievable levels of HCV treatment, especially with interferon-free direct-acting antiviral therapy (IFN-free DAAs), could substantially reduce HCV chronic prevalence among PWID within the next 10-20 years. In addition, modelling studies have shown HCV testing and treatment in prison (including prevention benefits) could be cost-effective if continuity of care is ensured, or HCV treatments are shortened with DAAs. Modelling work among HIV-infected MSM has shown that further HCV treatment scale-up is likely required despite high treatment rates in this population. However, no empirical studies have explored whether HCV treatment can reduce HCV prevalence and prevent onwards transmission among those at risk of transmission. SUMMARY: HCV treatment for key populations such as PWID, prisoners and MSM could become an important HCV prevention intervention, especially in the IFN-free DAA era. However, there is an urgent need to test these hypotheses through empirical studies.
PURPOSE OF REVIEW: The burden of hepatitis C virus (HCV) is high among people who inject drugs (PWID) and prisoners, and increasing among HIV-infected MSM, who are key populations for HCV transmission in high-income countries and may also play a role in many in low- and middle-income countries. There is an increasing interest in the use of HCV antiviral treatment for prevention in these populations. RECENT FINDINGS: Numerous theoretical modelling studies have explored the potential impact of HCV treatment for prevention among PWID in a range of global settings, generally finding that modest and achievable levels of HCV treatment, especially with interferon-free direct-acting antiviral therapy (IFN-free DAAs), could substantially reduce HCV chronic prevalence among PWID within the next 10-20 years. In addition, modelling studies have shown HCV testing and treatment in prison (including prevention benefits) could be cost-effective if continuity of care is ensured, or HCV treatments are shortened with DAAs. Modelling work among HIV-infected MSM has shown that further HCV treatment scale-up is likely required despite high treatment rates in this population. However, no empirical studies have explored whether HCV treatment can reduce HCV prevalence and prevent onwards transmission among those at risk of transmission. SUMMARY: HCV treatment for key populations such as PWID, prisoners and MSM could become an important HCV prevention intervention, especially in the IFN-free DAA era. However, there is an urgent need to test these hypotheses through empirical studies.
Authors: Belinda K Moessner; Tina R Jørgensen; Merete Skamling; Mogens Vyberg; Peter Junker; Court Pedersen; Peer B Christensen Journal: Addiction Date: 2010-12-23 Impact factor: 6.526
Authors: Kate Dolan; Suzy Teutsch; Nicolas Scheuer; Michael Levy; William Rawlinson; John Kaldor; Andrew Lloyd; Paul Haber Journal: Eur J Epidemiol Date: 2010-02 Impact factor: 8.082
Authors: Natasha K Martin; Peter Vickerman; Graham R Foster; Sharon J Hutchinson; David J Goldberg; Matthew Hickman Journal: J Hepatol Date: 2011-02-12 Impact factor: 25.083
Authors: Evan Wood; Thomas Kerr; Brandon D L Marshall; Kathy Li; Ruth Zhang; Robert S Hogg; P Richard Harrigan; Julio S G Montaner Journal: BMJ Date: 2009-04-30
Authors: Brendan Jacka; Tanya Applegate; Art F Poon; Jayna Raghwani; P Richard Harrigan; Kora DeBeck; M-J Milloy; Mel Krajden; Andrea Olmstead; Jeffrey B Joy; Brandon D L Marshall; Kanna Hayashi; Oliver G Pybus; Viviane Dias Lima; Gkikas Magiorkinis; Julio Montaner; Francois Lamoury; Gregory J Dore; Evan Wood; Jason Grebely Journal: J Hepatol Date: 2016-02-26 Impact factor: 25.083
Authors: Tanya L Applegate; Jason Grebely; Sofia R Bartlett; Joel O Wertheim; Rowena A Bull; Gail V Matthews; Francois Mj Lamoury; Konrad Scheffler; Margaret Hellard; Lisa Maher; Gregory J Dore; Andrew R Lloyd Journal: J Viral Hepat Date: 2016-11-24 Impact factor: 3.728
Authors: Sofia R Bartlett; Brendan Jacka; Rowena A Bull; Fabio Luciani; Gail V Matthews; Francois M J Lamoury; Margaret E Hellard; Behzad Hajarizadeh; Suzy Teutsch; Bethany White; Lisa Maher; Gregory J Dore; Andrew R Lloyd; Jason Grebely; Tanya L Applegate Journal: Infect Genet Evol Date: 2015-11-26 Impact factor: 3.342
Authors: Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer Journal: Lancet Date: 2016-03-24 Impact factor: 79.321